

Drug discovery
8
papers
On emerging therapies
Overview
Familial Scaphocephaly Syndrome is a rare craniosynostosis disorder characterized by premature fusion of the sagittal suture, leading to scaphocephaly (elongated skull), macrocephaly, severe maxillary retrusion, and mild intellectual disability in some cases. It is caused by a FGFR2 K526E mutation and follows autosomal dominant inheritance [7][15]. Diagnosis involves clinical evaluation, imaging, and genetic testing.
Burden
Physical: Risk of raised intracranial pressure (20–44%), skull deformities, and surgical complications (blood loss, reoperations) [12][8].
Developmental: Up to 37% experience speech delays; mild intellectual disability in severely affected males [7][12].
Psychosocial: Potential psychological impacts on self-esteem and family stress due to craniofacial differences [12][7].
Therapies
Early surgery: Endoscopic strip craniectomy with helmet therapy (before 4 months) or open cranial vault remodeling (after 4 months) [3][13][8].
Multidisciplinary care: Includes neurosurgeons, craniofacial specialists, and speech therapists to address developmental delays [12].
Genetic counseling: Recommended for families with identified FGFR2 mutations to discuss recurrence risks [7][15].